<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02214303</url>
  </required_header>
  <id_info>
    <org_study_id>SAIRA-1017/2012</org_study_id>
    <nct_id>NCT02214303</nct_id>
  </id_info>
  <brief_title>The Role of Th9 Cells and Eosinophils Activity in Allergic Airway Diseases</brief_title>
  <acronym>SAIRA</acronym>
  <official_title>The Role of Th9 Cells Expression and Eosinophils Activity in the Course of Allergic Airway Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lithuanian University of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lithuanian University of Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of allergic diseases, especially airway allergic diseases, has increased&#xD;
      dramatically over the last twenty years all over the world including Lithuania. Allergic&#xD;
      diseases are associated with significantly reduced quality of life and can sometimes cause&#xD;
      death. Allergic diseases have turned into an important economic and social burden and&#xD;
      nowadays take a more and more important place in the health system. Despite all intensive&#xD;
      investigations, the pathogenesis of allergic airway diseases still remains unclear. As&#xD;
      allergic diseases have a systemic pattern and multicomponent pathogenesis, it is important to&#xD;
      investigate not individual cells, but examine various inflammatory cells instead, including&#xD;
      their biological products and possible cellular interactions along the course of allergic&#xD;
      diseases. This research focuses on the cells that are claimed to be important in the&#xD;
      pathogenesis of allergic airway diseases, i.e. a newly found effector T helper cell subset&#xD;
      (Th9 cells), which still lacks deeper investigation, and the main inflammatory cell,&#xD;
      eosinophil. This study aims at determining the importance the way the Th9 lymphocytes&#xD;
      perform, the eosinophil's activity, as well as molecular factors affecting these cells has in&#xD;
      the process of prognostication of allergic airway diseases, namely allergic rhinitis and&#xD;
      allergic asthma. An allergen challenge test will be performed in order to define the meaning&#xD;
      of pathogenetic changes. The results of this research may reveal useful information in the&#xD;
      course of allergic diseases and may be valuable when creating strategic principles of&#xD;
      prophylaxis. The findings could be used for prevention and early diagnostics of allergic&#xD;
      diseases and it could also open doors to discovering new and effective treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Th9 cells and eosinophil apoptosis</measure>
    <time_frame>24 hours after bronchial allergen challenge</time_frame>
    <description>Blood and sputum eosinophils also peripheral blood th9 cells will be investigated.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Allergic Asthma</condition>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Allergic asthma</arm_group_label>
    <description>Allergic asthma (sensibilisation to D. pteronyssinus, 5 grass mixture allergens or birch pollen allergens)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allergic rhinitis</arm_group_label>
    <description>allergic rhinitis patients (sensibilisation to D. pteronyssinus, 5 grass mixture allergens or birch pollen allergens)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Healthy subjects</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Induced sputum and peripheral blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Allergic asthma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        I. Inclusion criteria:&#xD;
&#xD;
          1. Men and women between the ages of 18-50 years;&#xD;
&#xD;
          2. Allergic asthma (skin prick test positive for D. pteronyssinus, 5 grass mixture or&#xD;
             birch pollen);&#xD;
&#xD;
          3. Symptoms more than one year;&#xD;
&#xD;
          4. Positive Bronchial challenge with methacholine or documented completely reversible&#xD;
             bronchial obstruction;&#xD;
&#xD;
          5. Stable lung function (FEV1≥70 perc.);&#xD;
&#xD;
          6. Allergic rhinitis diagnosed according ARIA criteria.&#xD;
&#xD;
          7. Postmenopausal women. Premenopausal women if pregnancy test is negative&#xD;
&#xD;
          8. Healthy (subjects who are not sick with acute or chronic inflammatory, infectious,&#xD;
             oncologic or immune diseases) - control group&#xD;
&#xD;
          9. Participants who gave his/her informed written consent.&#xD;
&#xD;
        II. Exclusion criteria&#xD;
&#xD;
          1. Asthma and rhinitis exacerbation;&#xD;
&#xD;
          2. Clinically significant permanent allergy symptoms (ex. cat or dog dander induced&#xD;
             allergy);&#xD;
&#xD;
          3. Active airway infection 1 month prior the study;&#xD;
&#xD;
          4. Used medicaments:&#xD;
&#xD;
               1. Inhaled glucocorticoids intake 1 month prior the study;&#xD;
&#xD;
               2. Antihistamines intake 7 days prior the study;&#xD;
&#xD;
               3. Short acting β2 agonists 12 hours prior the study;&#xD;
&#xD;
               4. Long acting β2 agonists 2 days prior the study;&#xD;
&#xD;
               5. Leukotriene receptor antagonists prior 14 days;&#xD;
&#xD;
          5. If the histamine mean wheal diameter is &lt;= 3 mm or control mean wheal diameter is &gt;= 3&#xD;
             mm;&#xD;
&#xD;
          6. Psychiatric disorders;&#xD;
&#xD;
          7. Alcohol or narcotic abuse;&#xD;
&#xD;
          8. Pregnancy.&#xD;
&#xD;
          9. Breast-feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raimundas Sakalauskas, Prof., dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Lithuanian University of Health Sciences, Pulmonology and Immunology department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raimundas Sakalauskas, prof., dr.</last_name>
    <phone>376953</phone>
    <phone_ext>+370</phone_ext>
    <email>raimundas.sakalauskas@kaunoklinikos.lt</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deimante Hoppenot, MD</last_name>
    <phone>67439677</phone>
    <phone_ext>+370</phone_ext>
    <email>deimante@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lithuanian University of Health Sciences</name>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raimundas Sakalauskas, prof., dr.</last_name>
      <phone>37326953</phone>
      <phone_ext>+370</phone_ext>
      <email>raimundas.sakalauskas@kaunoklinikos.lt</email>
    </contact>
    <contact_backup>
      <last_name>Deimante Hoppenot, MD</last_name>
      <phone>67439677</phone>
      <phone_ext>+370</phone_ext>
      <email>deimante@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Lithuania</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>August 6, 2014</study_first_submitted>
  <study_first_submitted_qc>August 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2014</study_first_posted>
  <last_update_submitted>August 10, 2014</last_update_submitted>
  <last_update_submitted_qc>August 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lithuanian University of Health Sciences</investigator_affiliation>
    <investigator_full_name>Raimundas Sakalauskas</investigator_full_name>
    <investigator_title>prof., dr.</investigator_title>
  </responsible_party>
  <keyword>Allergic asthma</keyword>
  <keyword>Allergic rhinitis</keyword>
  <keyword>Healthy subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

